Champions Oncology (CSBR) FCF Margin (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly FCF Margin of 9.12% in Q1 2026, up 19.86% quarter-over-quarter from 11.39% in Q4 2025, and down 1120.0% on a YoY basis from 0.89% in Q1 2025.
Champions Oncology (CSBR) FCF Margin (2010 - 2026) Analysis & Trends
Champions Oncology's FCF Margin history runs 17 years deep, the most recent figure standing at 9.12% for Q1 2026.
- In Q1 2026, FCF Margin fell 1120.0% year-over-year to 9.12%; the TTM figure through Jan 2026 stood at 7.14% (up 959.0% YoY), while the FY2025 annual figure was 12.62%, up 2486.0% from the prior year.
- FCF Margin was 9.12% for Q1 2026 at Champions Oncology, up from 11.39% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 55.1% in Q2 2025 to a low of 37.09% in Q3 2023.
- Historically, FCF Margin has averaged 1.9% across 5 years, with a median of 2.08% in 2025.
- The sharpest annual moves came in 2023 and 2025: FCF Margin slumped 3019 bps in 2023, then jumped 6806 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 18.78% in 2022, then sank by 77 bps to 4.41% in 2023, then slumped by 148 bps to 2.1% in 2024, then plunged by 443 bps to 11.39% in 2025, then increased by 20 bps to 9.12% in 2026.
- The last three FCF Margin figures came in at 9.12% (Q1 2026), 11.39% (Q4 2025), and 3.96% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -9.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -9.12% |
| Oct 31, 2025 | -11.39% |
| Jul 31, 2025 | 3.96% |
| Apr 30, 2025 | 55.10% |
| Jan 31, 2025 | 2.08% |
| Oct 31, 2024 | -2.10% |
| Jul 31, 2024 | 2.21% |
| Apr 30, 2024 | -12.97% |
| Jan 31, 2024 | -1.43% |
| Oct 31, 2023 | 4.41% |
| Jul 31, 2023 | -37.09% |
| Apr 30, 2023 | -11.11% |
| Jan 31, 2023 | 6.41% |
| Oct 31, 2022 | 18.78% |
| Jul 31, 2022 | -6.90% |
| Apr 30, 2022 | 2.25% |
| Jan 31, 2022 | 29.20% |
| Oct 31, 2021 | 5.62% |
| Jul 31, 2021 | -6.14% |
| Apr 30, 2021 | -26.83% |